FDA Clearance Tracker · P230013-S027
EVOQUE Tricuspid Valve Replacement System
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Sep 16, 2026
Approved
Time to decision
180 days
Received Mar 20, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P230013-S027
- Device name
- EVOQUE Tricuspid Valve Replacement System
- Applicant
- Edwards Lifesciences, LLC
- Applicant location
- Irvine, CA
- Received
- Mar 20, 2026
- Decided
- Sep 16, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P230013
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for various modifications to the Instructions for Use, including the addition of internal jugular venous access and revision of the sizing table.
Source documents
Other decisions for Edwards Lifesciences, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PASCAL Precision Transcatheter Valve Repair SystemPMA supplement
P220003-S029 · Decided Oct 20, 2026 · 180 days after receipt · Panel Track
Device type: Tricuspid valve repair device, percutaneously delivered (NPS) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.